logo-loader
viewArecor

Arecor pushes to meet unmet needs in diabetes care

Snapshot

  • Biopharmaceuticals company developing superior diabetes care
  • Developing portfolio of of diabetes care treatments
  • Successfully completed phase I trial for ultra-rapid acting insulin
Arecor -

What Arecor does

Arecor Limited is a privately-owned biopharmaceuticals company developing superior diabetes care through the application of its innovative formulation technology platform.

Arecor is leveraging this platform to: 

(i) develop a portfolio of proprietary products for diabetes care

(ii) deliver superior reformulations of its partners proprietary products.

It partners with major pharma and biotech companies to develop improved versions of their key products, as well as developing its own products.

Inflexion points

In February, the firm inked a further collaboration agreement with a top five pharmaceutical company to develop a liquid formulation of a ready-to-administer (RTA) medicine using its Arestat technology.

The biopharma group said its partner will fund a feasibility study into the formula and will retain an exclusive option to a global royalty bearing licence for the product and Arecor’s associated IP.

In January, Arecor also signed an agreement with FTSE 100 firm Hikma Pharmaceuticals PLC (LON:HIK) to develop a new, ready-to-use injectable medicine.

The new product, to be announced prior to launch, will use Arecor’s Arestat drug formulation technology and is expected to be submitted to the US Food and Drug Administration for regulatory approval in 2021.

In December, Arecor hailed the successful completion of a phase I trial for its ultra-rapid acting insulin for diabetics, which it said had a “favourable profile” when compared with standard treatments.

The company said that its candidate, AT247, had finished a phase I double-blind, randomised study at The Medical University of Graz and Joanneum Research in Austria, in which it was measured against two other insulins on the market, NovoRapid and Fiasp.

Watch the interview

What the boss says

Sarah Howell, chief executive, called the completion of the phse 1 study “an important step” for the company’s goal to improve treatment and healthcare outcomes for people living with Type I diabetes.

“With AT247’s favourable profile over current treatments, we believe that our products have the potential to advance the diabetic treatment landscape," Howell said, noting that full data from the phase I study will be reported "in due course".

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arecor's Sarah Howell discusses results from successful phase I insulin trial

Arecor Ltd's CEO Sarah Howell caught up with Proactive London's Andrew Scott following the successful completion of the phase I trial for its ultra-rapid acting insulin for diabetics. She says the product was shown to have a favourable profile when compared with standard treatments and the...

on 17/12/19

2 min read